CN101537026A - Xuesaitong dispersible tablet and preparation method thereof - Google Patents
Xuesaitong dispersible tablet and preparation method thereof Download PDFInfo
- Publication number
- CN101537026A CN101537026A CN200910135650A CN200910135650A CN101537026A CN 101537026 A CN101537026 A CN 101537026A CN 200910135650 A CN200910135650 A CN 200910135650A CN 200910135650 A CN200910135650 A CN 200910135650A CN 101537026 A CN101537026 A CN 101537026A
- Authority
- CN
- China
- Prior art keywords
- parts
- dispersible tablet
- microcrystalline cellulose
- magnesium stearate
- crospolyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine, in particular to a xuesaitong dispersible tablet and a preparation method thereof. By weight, the material mixture ratios of the xuesaitong dispersible tablet are as follows: 80-100 parts of panax notoginseng saponins, 150-190 parts of microcrystalline cellulose, 8-10 parts of stevioside, 13-17 parts of crosslinked polyvinylpyrrolidone, 2-4 parts of aerosil and 1-3 parts of magnesium stearate. The preparation method comprises the steps of: taking the panax notoginseng saponins, the microcrystalline cellulose and the stevioside according to the mixture ratios and preparing soft materials by using 95% ethanol, then using a Number 3 sieve for pelletization; drying at temperature of 60 DEG C and obtaining particles after the pelletization of the Number 3 sieve; and adding the crosslinked polyvinylpyrrolidone, the aerosil and the magnesium stearate to the particles, evenly mixing, and tabletting, thus obtaining the dispersible tablet. The xuesaitong dispersible tablet has short disintegration time, fast acting property of medicaments, high bioavailability and good mouth feeling, thus being especially suitable to the use of children, old people and dysphagic patients. The invention has perfect technology and can save cost, and the quality can be controlled well.
Description
Technical field:
The present invention relates to Chinese medicine, particularly a kind of Xuesaitong dispersible tablet and preparation method thereof.
Background technology:
Existing XUESAITONG PIAN has blood circulation promoting and blood stasis dispelling, it is active to promote blood circulation, anticoagulant and cerebral blood flow increasing amount, is used for the stasis of blood resistance of brain road, apoplectic hemiplegia, the resistance of the heart arteries and veins stasis of blood, obstruction of qi in the chest and cardialgia; Apoplexy sequela, angina pectoris belong to above-mentioned symptom person.For the patient that cardiovascular and cerebrovascular disease is arranged, time is life.But former dosage form is the table sugar garment piece, prolonged disintegration, and the medicine stripping is slow, can not satisfy the demand that cardio-cerebral vascular disease patient is wished the rapid onset of medicine.
Summary of the invention:
It is short that the object of the invention aims to provide a kind of disintegration time, rapid-action, the bioavailability height, and mouthfeel is good, is fit to the Xuesaitong dispersible tablet of child, old age and dysphagia patients.
Another object of the present invention is to provide the preparation technology of a kind of technical maturity, Xuesaitong dispersible tablet quality controllable, with low cost.
The objective of the invention is to be achieved through the following technical solutions: Xuesaitong dispersible tablet by weight, proportioning raw materials is: 80～100 parts of Radix Notoginseng total arasaponinss, 150～190 parts of microcrystalline Cellulose, 8～10 parts of steviosides, 13～17 parts of crospolyvinylpyrrolidone, 2～4 parts of micropowder silica gels, 1～3 part of magnesium stearate.
Optimum material proportion of the present invention is: 100 parts of Radix Notoginseng total arasaponinss, 170 parts of microcrystalline Cellulose, 10 parts of steviosides, 15 parts of crospolyvinylpyrrolidone, 3 parts of micropowder silica gels, 2 parts of magnesium stearate.
Xuesaitong dispersible tablet of the present invention is made by following raw material in 1000: Radix Notoginseng total arasaponins 100g, microcrystalline Cellulose 170g, stevioside 10g, crospolyvinylpyrrolidone 15g, micropowder silica gel 3g, magnesium stearate 2g.
Preparation technology of the present invention is: press Radix Notoginseng total arasaponins 80～100 weight portions, microcrystalline Cellulose 150～190 weight portions, stevioside 8～10 weight portions, crospolyvinylpyrrolidone 13～17 weight portions, micropowder silica gel 2～4 weight portions, magnesium stearate 1～3 weight portion batching; Get the Radix Notoginseng total arasaponins in the said ratio, microcrystalline Cellulose, stevioside are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone in the granule, micropowder silica gel, the magnesium stearate mixing, tabletting, promptly.
Best preparation technology of the present invention is: get Radix Notoginseng total arasaponins 100g, microcrystalline Cellulose 170g, stevioside 10g are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone 15g in the granule, micropowder silica gel 3g, magnesium stearate 2g mixing, tabletting is made 1000.
With 95% ethanol system soft material, the ethanol consumption is the 7%-8% of medicated powder weight during granulation among the present invention, and unit is ml/g.
Compared with prior art, the present invention has the following advantages and good effect:
(1) select for use crospolyvinylpyrrolidone as disintegrating agent.Compare at present widely used have carboxymethyl starch sodium, the low replacement through propyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium etc., crospolyvinylpyrrolidone can make tablet meet behind the water the short as far as possible time (＜3min) in the very little granule of disintegrate one-tenth and form uniform suspension.
(2) select for use microcrystalline Cellulose to make the filler of tablet.Microcrystalline Cellulose is good tablet filler and double as binding agent, and it is good to have compressibility, unilateral characteristics attractive in appearance.
(3) select for use stevioside as correctives.Stevioside is a good correctives, and consumption is low, the sugariness height, and mouthfeel is good.
(4) select for use micropowder silica gel to make fluidizer.Micropowder silica gel can improve the flowability of granule or powder effectively when pelletizing press sheet or direct powder compression, simultaneously, can significantly improve the disintegrate and the dissolution rate of advising soluble drug behind the silanol base on the silica gel surface absorption medicine.
(5) select for use magnesium stearate to make lubricant.It is the excellent lubrication agent, and easy and granule mixing reduces the frictional force between granule and the punch die, and is unilateral bright and clean attractive in appearance behind the tabletting.
(6) selecting concentration 95% ethanol system soft material is wetting agent.Wetting agent water generally commonly used, ethanol etc.Because the present invention is raw material with the Chinese medicine extract, use water as wetting agent merely, the viscosity difficulty of sieving too greatly.So consider to make wetting agent with the ethanol of variable concentrations (75%, 85%, 95%).Through the result of the test that table 1 provides, select 95% concentration of alcohol optimum.It can be seen from the table, along with the reduction of moisture, particle viscosity reduces, and the slice, thin piece compressibility strengthens.
Table 1
| Concentration of alcohol | The situation of sieving | The granule ratio of sieving | Pellet hardness |
| 75％ | It is agglomerating to bond, sad sieve | 60％ | Very hard, difficult tabletting |
| 85％ | The fraction bonding is agglomerating, sad sieve | 80％ | Harder, tabletting pressure is big |
| 95％ | Easily sieve | 95％ | Hardness is moderate, easily presses |
(7) select suitable bake out temperature.The wet grain drying temperature generally is controlled at 60-80 ℃ and is advisable, and this temperature, gets final product so baking temperature is controlled at 60 ℃ because the present invention adopts 95% alcohol granulation not influence of active ingredient.
(8) the adding method of selection disintegrating agent.Adopt outer addition can reach disintegrate effect preferably (1 minute and 58 seconds).
(9) select critical relative humidity.Through the result of the test that table 2 provides, it is suitable that the relative humidity of environment is controlled at below 60%.
Table 2
The specific embodiment:
Embodiment 1: get Radix Notoginseng total arasaponins 100g, microcrystalline Cellulose 170g, stevioside 10g are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone 15g in the granule, micropowder silica gel 3g, magnesium stearate 2g mixing, tabletting is made 1000.Oral, a 50～100mg, 3 times on the one.
Embodiment 2: get Radix Notoginseng total arasaponins 80g, microcrystalline Cellulose 160g, stevioside 10g are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone 13g in the granule, micropowder silica gel 3g, magnesium stearate 2g mixing, tabletting is made 1000.Oral, a 50～100mg, 3 times on the one.
Claims (6)
1, a kind of Xuesaitong dispersible tablet is characterized in that, by weight, proportioning raw materials is: 80～100 parts of Radix Notoginseng total arasaponinss, 150～190 parts of microcrystalline Cellulose, 8～10 parts of steviosides, 13～17 parts of crospolyvinylpyrrolidone, 2～4 parts of micropowder silica gels, 1～3 part of magnesium stearate.
2, Xuesaitong dispersible tablet according to claim 1 is characterized in that, by weight, proportioning raw materials is: 100 parts of Radix Notoginseng total arasaponinss, 170 parts of microcrystalline Cellulose, 10 parts of steviosides, 15 parts of crospolyvinylpyrrolidone, 3 parts of micropowder silica gels, 2 parts of magnesium stearate.
3, Xuesaitong dispersible tablet according to claim 1 is characterized in that, Xuesaitong dispersible tablet is in 1000, make by following raw material: Radix Notoginseng total arasaponins 100g, microcrystalline Cellulose 170g, stevioside 10g, crospolyvinylpyrrolidone 15g, micropowder silica gel 3g, magnesium stearate 2g.
4, preparation is according to the technology of the said Xuesaitong dispersible tablet of claim 1, it is characterized in that, press Radix Notoginseng total arasaponins 80～100 weight portions, microcrystalline Cellulose 150～190 weight portions, stevioside 8～10 weight portions, crospolyvinylpyrrolidone 13～17 weight portions, micropowder silica gel 2～4 weight portions, magnesium stearate 1～3 weight portion batching; Get the Radix Notoginseng total arasaponins in the said ratio, microcrystalline Cellulose, stevioside are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone in the granule, micropowder silica gel, the magnesium stearate mixing, tabletting, promptly.
5, preparation is characterized in that according to the technology of the said Xuesaitong dispersible tablet of claim 4 get Radix Notoginseng total arasaponins 100g, microcrystalline Cellulose 170g, stevioside 10g are with 95% ethanol system soft material, with No. 3 sieve series grains; 60 ℃ of oven dry get granule behind No. 3 sieve granulate; Add crospolyvinylpyrrolidone 15g in the granule, micropowder silica gel 3g, magnesium stearate 2g mixing, tabletting is made 1000.
6, preparation is characterized in that according to the technology of the said Xuesaitong dispersible tablet of claim 5 with 95% ethanol system soft material, the ethanol consumption is the 7%-8% of medicated powder weight during granulation, and unit is ml/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910135650A CN101537026A (en) | 2009-04-24 | 2009-04-24 | Xuesaitong dispersible tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910135650A CN101537026A (en) | 2009-04-24 | 2009-04-24 | Xuesaitong dispersible tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101537026A true CN101537026A (en) | 2009-09-23 |
Family
ID=41120567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910135650A Pending CN101537026A (en) | 2009-04-24 | 2009-04-24 | Xuesaitong dispersible tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101537026A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102627680A (en) * | 2012-03-21 | 2012-08-08 | 浙江维康药业有限公司 | Ginsenoside Rg1 compound and pharmaceutical composition containing the same |
| CN105055476A (en) * | 2015-08-24 | 2015-11-18 | 江苏红瑞制药有限公司 | Radix notoginseng saponin dispersible tablet and preparing method thereof |
| CN113069426A (en) * | 2021-04-09 | 2021-07-06 | 海南海力制药有限公司 | Preparation method of Xuesaitong dispersion tablet and Xuesaitong dispersion tablet |
-
2009
- 2009-04-24 CN CN200910135650A patent/CN101537026A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102627680A (en) * | 2012-03-21 | 2012-08-08 | 浙江维康药业有限公司 | Ginsenoside Rg1 compound and pharmaceutical composition containing the same |
| CN102627680B (en) * | 2012-03-21 | 2013-04-03 | 浙江维康药业有限公司 | Ginsenoside Rg1 compound and pharmaceutical composition containing the same |
| CN105055476A (en) * | 2015-08-24 | 2015-11-18 | 江苏红瑞制药有限公司 | Radix notoginseng saponin dispersible tablet and preparing method thereof |
| CN105055476B (en) * | 2015-08-24 | 2019-01-15 | 江苏红瑞制药有限公司 | A kind of Xuesaitong dispersible tablet and preparation method thereof |
| CN113069426A (en) * | 2021-04-09 | 2021-07-06 | 海南海力制药有限公司 | Preparation method of Xuesaitong dispersion tablet and Xuesaitong dispersion tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784487A (en) | Ginseng micro-powder tablet and preparation method thereof | |
| CN105288215A (en) | High-activity dendrobium officinale kimura et migo freeze-drying powder buccal tablets and preparation process thereof | |
| CN101336904B (en) | Acarbose chewable tablets and preparation method thereof | |
| CN104523791A (en) | Orally disintegrating tablet containing fresh ginseng active extract and preparation method thereof | |
| CN104189502A (en) | Micronized dendrobium officinale tablet and preparation method thereof | |
| WO2018077275A1 (en) | Composition for protecting eyesight and preparation method therefor | |
| CN101129790A (en) | Compound hippophae rhamnoides lozenge method of producing the same | |
| CN101537026A (en) | Xuesaitong dispersible tablet and preparation method thereof | |
| CN101007071A (en) | Traditional Chinese medicine for treating acute and chronic gastroenteritis and bacterial dysentery and its processing technology | |
| CN103372047A (en) | Eucommia bark buccal tablets and preparation method thereof | |
| CN102335229B (en) | Preparation method of gynecological inflammation clearing vaginal effervescent tablet | |
| CN103381193B (en) | A kind of Rhodiola rosea micro powder tablet and preparation method thereof | |
| CN110338426A (en) | A kind of blood enriching effervescent tablet agent and preparation method thereof | |
| CN104069347A (en) | Preparation method of polygonatum odoratum total saponin dispersible tablet | |
| CN103301306A (en) | Korla bergamot pear lozenge for relieving cough and asthma | |
| CN1853670B (en) | Coronary heart Danshen root micropellets and preparation thereof | |
| CN104137999B (en) | The healthcare products that the dietetic therapeutic composition of a kind of fat-reducing of reducing weight and auxiliary material obtain and its preparation method | |
| CN107496477A (en) | A kind of sugar-free sanchi flower buccal tablet and its production technology | |
| CN100450504C (en) | Medication for treating pharyngitis | |
| WO2013177833A1 (en) | Dysmenorrhea-treating medicament and preparation method therefor | |
| CN108114250A (en) | A kind of ginger buccal tablet and preparation method thereof | |
| CN103719863B (en) | Preparation method of red ginseng chewable tablets | |
| CN106615528A (en) | Yin-nourishing and lung-clearing functional candies and preparation method thereof | |
| CN102085271A (en) | Composition for protecting liver | |
| CN104435033A (en) | Notoginseng flower and ginseng effervescent tablets and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090923 |